152 related articles for article (PubMed ID: 29337848)
1. Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland.
Parczewski M; Cielniak I; Kordek J; Aksak-Wąs B; Urbańska A; Leszczyszyn-Pynka M; Siwak E; Bociąga-Jasik M; Nowak A; Szymczak A; Zalewska M; Łojewski W; Vandamme AM; Lübke N; Cuypers L
J Acquir Immune Defic Syndr; 2018 Apr; 77(5):514-522. PubMed ID: 29337848
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
[TBL] [Abstract][Full Text] [Related]
3. The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
Newsum AM; Ho CK; Lieveld FI; van de Laar TJ; Koekkoek SM; Rebers SP; van der Meer JT; Wensing AM; Boland GJ; Arends JE; van Erpecum KJ; Prins M; Molenkamp R; Schinkel J
AIDS; 2017 Jan; 31(1):105-112. PubMed ID: 27898592
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients.
Nevot M; Boesecke C; Parera M; Andrés C; Franco S; Revollo B; Ingiliz P; Tural C; Clotet B; Rockstroh JK; Martinez MA;
J Viral Hepat; 2014 Jun; 21(6):e19-28. PubMed ID: 24674023
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
Sarrazin C; Lathouwers E; Peeters M; Daems B; Buelens A; Witek J; Wyckmans Y; Fevery B; Verbinnen T; Ghys A; Schlag M; Baldini A; De Meyer S; Lenz O
Antiviral Res; 2015 Apr; 116():10-6. PubMed ID: 25614456
[TBL] [Abstract][Full Text] [Related]
6. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
Bagaglio S; Uberti-Foppa C; Messina E; Merli M; Hasson H; Andolina A; Galli A; Lazzarin A; Morsica G
Clin Microbiol Infect; 2016 Apr; 22(4):386.e1-386.e3. PubMed ID: 26706617
[TBL] [Abstract][Full Text] [Related]
7. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
[TBL] [Abstract][Full Text] [Related]
9. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.
Beloukas A; King S; Childs K; Papadimitropoulos A; Hopkins M; Atkins M; Agarwal K; Nelson M; Geretti AM
Clin Microbiol Infect; 2015 Nov; 21(11):1033-9. PubMed ID: 26232533
[TBL] [Abstract][Full Text] [Related]
10. Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing.
Caro-Pérez N; Martínez-Rebollar M; Gregori J; Quer J; González P; Gambato M; García-González N; González-Candelas F; Costa J; Esteban JI; Mallolas J; Forns X; Laguno M; Pérez-Del-Pulgar S
J Clin Virol; 2017 Jul; 92():42-47. PubMed ID: 28521213
[TBL] [Abstract][Full Text] [Related]
11. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.
Ogishi M; Yotsuyanagi H; Tsutsumi T; Gatanaga H; Ode H; Sugiura W; Moriya K; Oka S; Kimura S; Koike K
PLoS One; 2015; 10(3):e0119145. PubMed ID: 25748426
[TBL] [Abstract][Full Text] [Related]
12. Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection.
Lieveld FI; Swaans N; Newsum AM; Ho CK; Schinkel J; Molenkamp R; van der Meer JT; Arends JE; Hoepelman AI; Wensing AM; Siersema PD; van Erpecum KJ; Boland GJ
Ann Hepatol; 2016; 15(5):696-704. PubMed ID: 27493108
[TBL] [Abstract][Full Text] [Related]
13. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
14. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
[TBL] [Abstract][Full Text] [Related]
15. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan.
Tsai MC; Hung CH; Lu SN; Wang JH; Chen CH; Kee KM; Chang KC; Chao TL; Hu TH
Biomed J; 2021 Dec; 44(6 Suppl 1):S126-S131. PubMed ID: 35123932
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
[TBL] [Abstract][Full Text] [Related]
18. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.
Li Z; Liu Y; Zhang Y; Shao X; Luo Q; Guo X; Lin G; Cai Q; Zhao Z; Chong Y
Biomed Res Int; 2017; 2017():9849823. PubMed ID: 29164151
[TBL] [Abstract][Full Text] [Related]
19. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
[TBL] [Abstract][Full Text] [Related]
20. Limited overlap between phylogenetic HIV and hepatitis C virus clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM.
Vanhommerig JW; Bezemer D; Molenkamp R; Van Sighem AI; Smit C; Arends JE; Lauw FN; Brinkman K; Rijnders BJ; Newsum AM; Bruisten SM; Prins M; Van Der Meer JT; Van De Laar TJ; Schinkel J;
AIDS; 2017 Sep; 31(15):2147-2158. PubMed ID: 28692530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
